aripiprazole has been researched along with ru 66647 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gagne, JJ; Maclure, M; Schneeweiss, S; Wang, SV | 1 |
Hashiguchi, M; Imai, S; Maruyama, J; Mochizuki, M; Shimizu, M; Uehara, K | 1 |
2 other study(ies) available for aripiprazole and ru 66647
Article | Year |
---|---|
"First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs.
Topics: Anti-Bacterial Agents; Antipsychotic Agents; Aripiprazole; Bias; Case-Control Studies; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Databases, Pharmaceutical; Humans; Isoxazoles; Ketolides; Marketing; Medicaid; Pharmacoepidemiology; Piperazines; Product Surveillance, Postmarketing; Quinolones; Sulfonamides; United States | 2014 |
Factors Affecting the Timing of Signal Detection of Adverse Drug Reactions.
Topics: Adverse Drug Reaction Reporting Systems; Aripiprazole; Chemical and Drug Induced Liver Injury; Data Mining; Databases, Factual; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Exenatide; Humans; Hypercalcemia; Ketolides; Pancreatitis; Peptides; Rhabdomyolysis; Rosuvastatin Calcium; Suicide; Teriparatide; Time Factors; United States; United States Food and Drug Administration; Varenicline; Venoms | 2015 |